# V1 Empirics Check — moonshotai/kimi-k2.5 (Variant C)

**Model:** moonshotai/kimi-k2.5
**Variant:** C
**Date:** 2026-03-30T11:38:38.826898

---

 **Review of "The Loyalty Penalty Ban: Consumer Complaints and Insurer Pricing after the UK's Price-Walking Reform"**

---

### 1. Idea Fidelity

The paper successfully pursues the original manifest. It implements the cross-product difference-in-differences design comparing motor/property (treated) against pet/medical/warranty/assistance (controls) using FCA aggregate complaints data and Bank of England underwriting statistics. The identification strategy, data sources, and exclusion of travel insurance (COVID-confounded) match the proposal. The paper correctly identifies the few-cluster inference challenge and attempts wild bootstrap and randomization inference, as anticipated in the feasibility discussion.

---

### 2. Summary

This paper evaluates the UK's 2022 prohibition on insurance "price-walking" (charging renewal customers more than new customers) using a cross-product difference-in-differences design that exploits the reform's narrow scope—applying only to motor and home insurance while leaving other lines unregulated. The author finds that complaint rates per 1,000 policies fell by 1.87 (a 55% relative reduction) for treated products, though this estimate is sensitive to inference method and pre-trends.

---

### 3. Essential Points

**1. Pre-trends violate the parallel trends assumption.** The event study (Table 3) reveals a massive convergence pattern prior to treatment: the treated-control gap falls from 2.16 (≤2019 H1) to 0.14 (2021 H1)—nearly complete convergence *before* the January 2022 ban. The placebo test (Table 4) confirms this concern: assigning a fictitious 2020 H1 treatment yields a coefficient of –1.33 (comparable to the main estimate of –1.87), suggesting the DiD estimator captures a pre-existing trend rather than a causal policy effect. The paper acknowledges this but does not adequately address it; without a valid strategy to difference out this trend (e.g., synthetic control, matched trends, or pre-trend adjustment), the causal interpretation is unsupported.

**2. Few-cluster inference invalidates the primary significance claims.** With only six or seven product-level clusters, standard cluster-robust inference is unreliable and anti-conservative. The paper transparently reports wild cluster bootstrap ($p = 0.229$) and randomization inference ($p = 0.292$) $p$-values, which fail to reject the null at conventional levels. Yet the abstract and conclusions emphasize the cluster-robust $p = 0.016$. In a design with fewer than ten clusters, standard errors collapse and over-reject; the conservative bounds are the appropriate inference. The paper cannot claim a statistically significant effect.

**3. The "55% reduction" is an artefact of control group divergence, not treated improvement.** Table 1 shows that treated complaint rates fell only modestly (3.42 to 3.01, a 12% absolute decline), while control rates surged (3.05 to 4.08, a 34% increase). The DiD estimate reflects this divergence—driven by massive, unexplained increases in medical/health (+47%) and pet/warranty complaints—rather than a reduction in consumer harm among treated policyholders. The control group is clearly invalid: post-COVID disruptions (backlogs in private medical insurance, pandemic-related coverage disputes) created structural breaks in control products unrelated to the price-walking ban. Without a credible counterfactual, the economic interpretation is misleading.

---

### 4. Suggestions

**Address the pre-trend problem directly.** The convergence prior to 2022 suggests anticipatory effects (firms adjusting prices ahead of the ban), secular trends in consumer search behavior, or differential exposure to the 2021 Consumer Duty. You should: (a) test for anticipatory effects using leads of treatment; (b) implement the Rambachan & Roth (2023) sensitivity analysis for DiD with pre-trends to report how much the pre-trend would need to change to invalidate your results; and (c) consider a synthetic control approach using the pre-treatment period to construct a better counterfactual from the control pool, or use the synthetic DiD method of Arkhangelsky et al. (2021) given the clear trending behavior.

**Clarify the economic mechanism.** Why would banning price-walking reduce complaints *per 1,000 policies*? The ban equalizes prices between new and renewal customers, but standard theory predicts this redistributes surplus rather than reducing total complaints. If anything, higher new-business prices (confirmed in your BoE results) might increase complaints from new customers. You hypothesize that the reduction reflects eliminated "consumer friction," but you need to distinguish between (a) fewer complaints *about price increases at renewal* (plausible) and (b) fewer total complaints (requires explaining why other complaint categories fell). If motor complaints stayed flat while health/pet surged due to post-COVID service issues, your estimate captures differential sectoral shocks, not consumer protection.

**Reformulate the control group or add a triple-difference.** The medical/health and pet insurance markets underwent fundamentally different shocks than motor during 2020–2024 (telemedicine disputes, veterinary supply chains, pandemic coverage exclusions). Consider: (a) dropping medical/health and pet as controls, using only assistance/warranty (though this reduces power further); (b) using a triple-difference design that interacts the product-level treatment with firm-level exposure if microdata becomes available; or (c) leveraging the FOS escalation data mentioned in the manifest as a falsification test—if the ban reduced "bad" complaints, escalated ombudsman cases should also fall for treated lines relative to controls.

**Improve the event study specification.** Binning all pre-2019 periods into a single coefficient (Table 3) obscures the trend dynamics. Report semiannual coefficients for all periods with Sun & Abraham (2021) or Callaway & Sant'Anna (2021) confidence intervals appropriate for staggered designs (even with sharp timing, these estimators handle heterogeneous treatment effects better than TWFE). Show the full dynamic path rather than endpoint bins.

**Rethink the standardized effect sizes table.** Table A.3 reports SDEs but the classification ("Large negative" based on arbitrary thresholds) adds little. The SDE of –8.3 for Property is implausibly large and driven by the low standard deviation (0.20)—likely because Property has a flat trajectory with minimal variance, making it a poor treated unit for DiD. Consider disaggregating Motor and Property completely; they may have different treatment effects and pre-trends.

**Address the July 2023 Consumer Duty.** The paper notes the Consumer Duty applies to all lines and is absorbed by time FE, but if it affects complaints differentially (e.g., medical insurers face stricter conduct requirements than motor insurers), it contaminates the post-2023 periods. Test for breaks at July 2023 using an interaction or truncate the sample at 2022 H2–2023 H1 to isolate the pure price-walking effect before the Duty fully bit.

**Be explicit about the denominator.** "Complaints per 1,000 policies" requires that "provision" (policies in force) is measured accurately. If insurers responded to the ban by adjusting policy durations or churn rates, the denominator changes endogenously. Report robustness using raw complaint counts or per-£-of-premium measures if possible.

**Final note on publication prospects.** The core contribution—demonstrating that regulatory evaluation is possible with public data—is valuable. However, the empirical results are currently too fragile for an AER: Insights piece given the pre-trends and inference issues. Consider reframing as a "methods demonstration" showing how cross-product designs *can* be implemented, while being honest that this particular application yields imprecise null effects due to trending controls and few clusters. Alternatively, secure firm-level data to implement a within-product continuous DiD that complements the FCA's evaluation, rather than competing with it using a noisier design.
